智通财经APP讯，白云山(600332.SH)公告，近日，公司子公司广州白云山汉方现代药业有限公司(简称“白云山汉方”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，药物名称为LBZ-18、LBZ-18口服乳。
根据《中华人民共和国药品管理法》及有关规定，经审查，2024年10月28日受理的LBZ-18口服乳(CXZL2400071)、LBZ-18(CXZL2400070)临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品制剂开展用于癌因性疲乏的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.